Cannabis legalization spurs innovation, but not always in ways that benefit patients or public health

Economists studying institutional changes found that recreational cannabis legalization spurs innovation, primarily expanding commercial opportunities rather than scientific understanding or health benefits. Their research analyzed cannabis-related clinical trials and patent applications, categorizing them by focus, such as chemical formulations or medical uses. This innovation often targets consumers directly through high-potency formulations, edibles, or vaporizers. The findings indicate that while state legalization lowers costs for product development, it does not necessarily advance medical research or patient benefits. This occurs despite the U.S. federal government classifying cannabis as a Schedule I drug with "no accepted medical use."